NextCell Pharma AB Reports Increased Losses in Q3

NextCell Pharma AB, a biotechnology company specializing in tissue establishment and primary biobanking, has reported an increased loss for the third quarter of its fiscal year 2024/2025. The company, headquartered in Huddinge, Sweden, and listed on the Swedish Stock Exchange, disclosed a net loss of SEK -10.4 million for the period from March to May 2025, compared to a loss of SEK -9.0 million in the same quarter of the previous year.

NextCell Pharma AB focuses on developing novel treatments using stem cells from the umbilical cord for therapeutic immunomodulation of autoimmune and inflammatory diseases, including transplantation applications. Despite its innovative approach, the company continues to face financial challenges, as evidenced by the increased quarterly loss.

The company’s financial performance is reflected in its stock price, which closed at SEK 1.148 on July 22, 2025. This represents a significant decline from its 52-week high of SEK 3.84 on February 27, 2025, and a rise from its 52-week low of SEK 0.69 on April 14, 2025. The market capitalization stands at SEK 114,730,000, with a price-to-earnings ratio of -1.73, indicating ongoing financial difficulties.

NextCell Pharma AB published its Interim Report 3 for the fiscal year 2024/2025, providing further insights into its financial status and strategic direction. The company remains committed to its mission of advancing stem cell therapies, despite the current financial setbacks.

For more detailed information about NextCell Pharma AB and its activities, interested parties can visit the company’s website at www.nextcellpharma.com .